Centessa reports Q1 net loss $50.7M, cash $346.2M; advancing SerpinPC, LB101 trials

Centessa Pharmaceuticals plc

2023-Q1 EPS reported -$0.53

Cash $346.2M as of Mar 31, expected to fund operations into 2026; no draw on Oberland credit facility.
Net loss attributable to shareholders $50.7M vs $54.5M YoY; R&D $32.8M (down 11%), G&A $16.1M (up 12%).
SerpinPC registration program for hemophilia B ongoing; PRESent-5 enrolling; PRESent-2/3 dosing expected H2 2023.
LB101 (PD-L1xCD47 LockBody) Phase 1/2a first-in-human trial dosing subjects for solid tumors.
ORX750 (OX2R agonist for narcolepsy) in IND-enabling activities; preclinical data planned at 2023 scientific meeting.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Centessa Pharmaceuticals plc reported the first quarter ended March 31, 2023 results: net income Net Loss Attributable to Ordinary Shareholders: $50.7 million.

Period: the first quarter ended March 31, 2023
Net income: Net Loss Attributable to Ordinary Shareholders: $50.7 million
Result: reported results

Exact text from the filing

Centessa Pharmaceuticals plc (the “Company”) announced its financial results for the quarter ended March 31, 2023.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Centessa Pharmaceuticals plc filing history →

Source: SEC EDGAR

accession 0001847903-23-000095

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.